EyePoint, Inc. (EYPT)
| Market Cap | 1.13B +146.7% |
| Revenue (ttm) | 7.61M -86.4% |
| Net Income | -271.60M |
| EPS | -3.51 |
| Shares Out | 83.84M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 838,320 |
| Open | 13.45 |
| Previous Close | 13.62 |
| Day's Range | 13.21 - 13.60 |
| 52-Week Range | 5.30 - 19.11 |
| Beta | 1.77 |
| Analysts | Strong Buy |
| Price Target | 31.40 (+133.81%) |
| Earnings Date | May 6, 2026 |
About EYPT
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet ... [Read more]
Financial Performance
In 2025, EyePoint's revenue was $31.37 million, a decrease of -27.50% compared to the previous year's $43.27 million. Losses were -$231.96 million, 77.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for EYPT stock is "Strong Buy." The 12-month stock price target is $31.4, which is an increase of 133.81% from the latest price.
News
EyePoint reports Q1 EPS (99c), consensus (81c)
Reports Q1 revenue $696,000, consensus $352,830. “We are entering an important time for EyePoint (EYPT) and the retina community with Phase 3 topline data for DURAVYU in wet AMD expected…
EyePoint Earnings Call Transcript: Q1 2026
Q1 2026 saw strong clinical and operational progress, with pivotal DURAVYU phase III trials advancing in wet AMD and DME, robust safety data, and commercial readiness activities underway. Cash reserves of $223M support operations into late 2027.
EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments
WATERTOWN, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with se...
EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026
WATERTOWN, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with ...
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with seriou...
EyePoint Transcript: RBC Capital Markets Virtual Ophthalmology Conference
DURAVYU is advancing through four phase III trials for wet AMD and DME, with strong safety and efficacy data supporting non-inferiority to EYLEA and significant reduction in treatment burden. Top-line results for LUGANO are expected in August, and the company is well-funded through 2027.
EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug
EyePoint filed a lawsuit on Friday accusing rival Ocular Therapeutix of spreading false or misleading information about EyePoint and its lead experimental eye drug.
EyePoint reports inducement grants under NASDAQ listing rule
EyePoint (EYPT) granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Com...
EyePoint price target raised to $35 from $31 at Citi
Citi raised the firm’s price target on EyePoint (EYPT) to $35 from $31 and keeps a Buy rating on the shares.
EyePoint price target raised to $30 from $23 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen raised the firm’s price target on EyePoint (EYPT) to $30 from $23 and keeps a Buy rating on the shares following the Q4 report. The…
EyePoint price target raised to $29 from $27 at Chardan
Chardan raised the firm’s price target on EyePoint (EYPT) to $29 from $27 and keeps a Buy rating on the shares. The firm is updating estimates after the company reported…
EyePoint Earnings Call Transcript: Q4 2025
DURAVYU advanced through pivotal Phase III trials in wet AMD and DME, supported by strong safety and efficacy data, robust cash reserves, and expanded commercial readiness. Top-line data for wet AMD is expected in mid-2026, with DME data in 2027.
EyePoint reports Q4 EPS (81c), consensus (75c)
Reports Q4 revenue $620k, consensus $1.01M. “Following a year of exceptional execution across our pivotal DURAVYU programs, EyePoint (EYPT) enters 2026 from a position of strength as we prepare to…
EyePoint expects cash to fund operations into Q4 2027
The company expects the cash, cash equivalents, and investments on December 31, 2025, will enable to fund operations into the fourth quarter of 2027 beyond key milestones for the Phase…
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments
– Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 – – Patients dosed in both COMO and CAPRI Phase 3 clinical trials for DURAVYU in DME – – Michael Ca...
EyePoint Transcript: TD Cowen 46th Annual Health Care Conference
Phase III DME trials are underway with full enrollment expected by Q3 2024 and top-line data in Q4 2027. The drug's unique IL-6 blockade and sustained-release profile may offer significant advantages in wet AMD and DME, targeting a combined $15 billion global market.
EyePoint announces first patients dosed in Global Phase 3 trials of DURAVYU
EyePoint (EYPT) announced the first patient dosed in both Phase 3 COMO and CAPRI global clinical trials of DURAVYU for the treatment of diabetic macular edeme. DURAVYU is an investigational…
EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema
– Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets –
EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026
WATERTOWN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with s...
EyePoint Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with s...
EyePoint price target raised to $36 from $33 at Mizuho
Mizuho raised the firm’s price target on EyePoint (EYPT) to $36 from $33 and keeps an Outperform rating on the shares.
EyePoint appoints Campbell as Chief Commercial Officer
EyePoint (EYPT) announced that Michael Campbell has been appointed Chief Commercial Officer. Campbell will assume responsibility for EyePoint’s commercial strategy and launch readiness for Duravyu, cu...
EyePoint Appoints Michael Campbell as Chief Commercial Officer
– Seasoned commercial executive with over 30 years of leadership in retinal disease across biotech and large pharma – – Brings established track record of successful product launches and oversight of ...
EyePoint reports inducement grants under NASDAQ listing rule
EyePoint (EYPT) announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listi...
EyePoint Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Two pivotal phase III wet AMD trials are fully enrolled, with LUGANO data expected mid-year and DME trials underway. DURAVYU aims for six-month dosing, strong safety, and broad market potential, with robust financials supporting programs into 2027.